Hi-Tech Pharmacal
This article was originally published in The Tan Sheet
Executive Summary
Year-end sales rose to $56.4 mil., up 19% from the prior-year period, the company announces July 13. Net income for the fiscal year ended April 30 increased 15% to $6.6 mil., the Amityville, N.Y.-based company says. Although the Health Care Products division saw a 9% sales decrease, revenue for the DiabetiDerm line increased by 46%, which the firm attributes to strong sales of the line's foot cream containing L-Arginine. The company says it "intends to stay focused on branded products targeting the diabetes market and related areas, including podiatry and dermatology." Hi-Tech Pharmacal identified its increasing interest in products for diabetics last year (1"The Tan Sheet" Sept. 29, 2003, p. 10)...
You may also be interested in...
Hi-Tech Diabetic Products To Play Key Role In Firm’s Growth Strategy
Hi-Tech Pharmacal plans to build up its Health Care Products Division through a two-pronged approach involving launching new products aimed at diabetics and expanding distribution channels
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.